AU717720B2 - Process for preparing 1,4,7,10-tetraazacyclododecane and its derivatives - Google Patents

Process for preparing 1,4,7,10-tetraazacyclododecane and its derivatives Download PDF

Info

Publication number
AU717720B2
AU717720B2 AU18772/97A AU1877297A AU717720B2 AU 717720 B2 AU717720 B2 AU 717720B2 AU 18772/97 A AU18772/97 A AU 18772/97A AU 1877297 A AU1877297 A AU 1877297A AU 717720 B2 AU717720 B2 AU 717720B2
Authority
AU
Australia
Prior art keywords
derivative
benzylaziridine
substituted
derivatives
sulfuric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU18772/97A
Other versions
AU1877297A (en
Inventor
Klaus Graske
Klaus Nickisch
Orlin Petrov
Johannes Platzek
Annette Prelle
Bernd Raduchel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU1877297A publication Critical patent/AU1877297A/en
Application granted granted Critical
Publication of AU717720B2 publication Critical patent/AU717720B2/en
Assigned to BAYER INTELLECTUAL PROPERTY GMBH reassignment BAYER INTELLECTUAL PROPERTY GMBH Alteration of Name(s) in Register under S187 Assignors: SCHERING AKTIENGESELLSCHAFT
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The invention concerns a process for preparing 1,4,7,10-tetraazacyclododecane (cyclene) and its derivatives on an industrial scale by the cyclotetramerization of benzylaziridine prepared in situ.

Description

The cyclotetramerization of N-substituted aziridines offers a method for the production of 1, 4 7 that appears to be basically simpler. Various variants of this reaction are described in the literature. In this case, the corresponding N-substituted aziridine is first produced from benzylethanolamine and isolated. Aziridine is then cyclotetramerized at low yield in the presence of Brdnsted acids, such as, p-TsOH Heterocyclic Chem. 1968, 305) or Lewis acids, such as trialkylaluminum (US Pat. 3,828,023) or BF 3 etherate (Tetrahedron Letters, 1970, 1367). Although the process can be implemented only for the production of small amounts 5 it is still the state of the art 16 years after the first publication (WO 95/31444).
All previously described cyclotetramerization reactions require the use of pure aziridines, which, as is generally known, have strong mutagenic and carcinogenic action (Roth, Giftliste, VCH Weinheim). For this reason, the cyclotetramerization of aziridines, which seems to be the simplest method for the production of 1, 4 7 ,10-tetraazacyclododecane, is virtually unused on an industrial scale. There is therefore a great deal of interest in a technically practicable process for the production of 1, 4 7 ,10-tetraazacyclododecane that is basically environmentally benign and largely safe.
The object of this invention is therefore to provide a practicable process for the production of 1,4,7,10tetraazacyclododecane on an industrial scale, which process overcomes the above drawbacks and in particular avoids the threat to humans posed by mutagenic and carcinogenic aziridine intermediate stages.
This object is achieved by the process according to the invention, as it is characterized in the claims.
In this case, this is a process for the production of cyclene derivatives by cyclotetramerization of benzylaziridine derivatives, characterized in that the benzylaziridine derivative is produced in situ and is tetramerized without isolation into a tetrabenyzlcyclene derivative with the addition of a strong acid, and finally the benzyl groups are removed by hydrogenation.
Within the framework of this invention, the term cyclene derivatives is intended to comprise both 1,4,7,10tetraazacyclododecane and those derivatives in which the ethylene bridges have alkyl substituents. The term cyclene derivative thus also relates to, for example, the compounds [2S- (2a,5a,8a,lla)]-2,5,8,11-tetramethyl-1,4,7,10tetraazacyclododecane and [2S-(2a,5a,8a,1a)]-2,5,8,11tetraethyl-l,4,7,10-tetraazacyclododecane.
Analogously, the term tetrabenzylcyclene derivatives within the framework of this invention is intended to comprise both 1,4,7,10-tetrabenzyl-l,4,7,10-tetraazacyclododecane and those derivatives in which the ethylene bridges have alkyl substituents. The term benzylaziridine derivative within the framework of this invention is intended to comprise benzylaziridine and those derivatives in which the aziridine ring has alkyl substituents. The term benzylaziridine derivative thus also relates to, for example, the compounds (S)-l-benzyl-2methyl-aziridine and (S)-l-benzyl-2-ethyl-aziridine.
The invention therefore relates to a process for the production of optionally substituted 1,4,7,10tetraazacyclododecane derivatives by tetramerization of corresponding educts. The invention preferably relates to the production of 1,4,7,10-tetraazacyclododecane.
A preferred embodiment of the process starts from readily accessible benzylethanolamine, which is converted by heating 150 0 C, preferably 90-110 0 C) with 1-1.4 equivalents of concentrated sulfuric acid in an organic solvent toluene, cyclohexane, heptane, concentration: 10-20%) and azeotropic distillation of the water that is produced in this case into the corresponding sulfuric acid ester. The reaction time in this case is 2-10 hours. The latter is heated with equivalents of an aqueous alkaline solution NaOH, KOH), and the benzylaziridine that is produced in this case in a second reaction vessel, which together with the first forms a closed system, is continuously azeotropically distilled off with water.
The aqueous benzylaziridine emulsion that is thus formed can, after dilution with an organic solvent ethanol, methanol, THF), be reacted surprisingly completely to form tetrabenzylcyclene by continuous addition of at least 0.25-0.4 mol (preferably 0.25-0.35 mol) of a strong acid per mol of benzylaziridine equivalent amount of acid relative to the product). As an organic solvent, ethanol, methanol, or tetrahydrofuran (THF) can be used. As a strong acid, for example, para-toluenesulfonic acid (p-TsoH), methanesulfonic acid (MsOH), sulfuric acid, or BF 3 -etherate can be used. After the reaction mixture is alkalized (0.2-0.5 equivalent of base, e.g., NaOH, KOH), the product is obtained by crystallization from polar solvents THF, ethanol, acetone, isopropanol, diethyl ether, ethyl acetate, furan, dioxane, water or their mixtures) and is then hydrogenated in an organic solvent (ethanol, methanol, isopropanol, THF) with the aid of a catalyst (Pd/C, amount 5-20% relative to the tetrabenzylcyclene derivative, pressure: 1-20 bar). After the catalyst is filtered and the solvent is distilled off, 1, 4 7 ,10-tetraazacyclododecane is obtained at a yield of 45-60% of the theoretical total yield.
Analogously to this synthesis, alkyl-substituted benzylethanolamine can also be used, L-2benzylaminopropanol or L-2-benzylaminobutanol, to obtain cyclene derivatives that have branches in the ethylene bridges. In a preferred embodiment of this synthesis, (S)-l-benzyl-2-methylaziridine is produced analogously to the above-described process from L-2-benzylaminopropanol and is reacted without isolation to form 2
S-(
2 a,5a,8a,lla)]-2,5,8,11-teetramethyl-,4,7,10tetrakis(benzyl)-1,4,7,10-tetraazacyclododecane by tetramerization, from which (2S-(2a,5a,8a,1a)]-2,5,8,11tetramethyl-1,4,7,10-tetraazacyclododecane is obtained by hydrogenation.
The process of cyclotetramerizing the benzylaziridine derivatives according to the invention differs from the process that is known in the prior art in that no isolation of the aziridine in pure form is necessary. The procedure described thus makes it possible to carry out the process in a closed system and thus to avoid the threat posed to humans and the environment by aziridine, which is carcinogenic.
In contrast to the process for cyclotetramerizing benzylaziridine that is known in the prior art, a stoichiometric amount (0.25-0.35 mol relative to one mol of benzylaziridine) is used instead of a catalytic amount of an acid (p-TsOH, MsOH, sulfuric acid, BF 3 -etherate or trialkylaluminum). In tests to scale up the known process and to be able to produce large amounts of 1, 4 ,7,10-tetraazacyclododecane in this process, only 12-25% of theoretical yield was achieved using catalytic amounts of p-TsOH in the reaction of the benzylaziridine emulsion that is produced in situ. It has now been found, surprisingly enough, that by continuously adding 0.25 to 0.35 equivalent of p-TsOH (relative to the benzylaziridine) to the azeotropically distilled-off benzylaziridine emulsion at 60-78 0 C within 6-9 hours, the yield of 1,4,7,10-tetrabenzyl-1,4,7,10tetraazacyclododecane can be improved to 60-65% of the theoretic yield.
Other advantages of this process are the high overall yield and small amounts of waste (Na-sulfate in the case of aziridine production and toluene in the case of hydrogenation) in contrast to known processes.
7 WO/97/31905 PCT/EP97/00927 Embodiments: The following examples are to explain the subject of the invention without intending that they be limited to this subject.
Example 1 53 ml of concentrated sulfuric acid is added to a solution of 95 ml of benzylethanolamine in 690 ml of toluene. The suspension that is produced is heated to boiling for 2 hours.
The water that is produced in this case (14 ml) is separated with the aid of a water separator. After cooling to 20 0 C, the reaction mixture is mixed with 1300 ml of water and absorptively precipitated for 10 minutes, and the organic phase is separated.
Then, the aqueous phase is quickly added to a solution of 92.2 g of NaOH in 95 ml of water that is introduced into a second reaction vessel. The reaction mixture is heated to boiling. 880 g of water-N-benzylaziridine emulsion in a third reaction vessel is distilled off through a distillation bridge. The emulsion is mixed with 880 ml of ethanol and heated to 60 0 C. To this end, a solution of 38.0 g of p-TsOH in 19 ml of water is added within 8 hours via a metering pump. After the addition is completed, it is refluxed for two hours. Then, the reaction mixture is mixed with a solution of 12.0 g of NaOH in 20 ml of water. The precipitated product is filtered and recrystallized from 600 ml of 2:1 ethanol-THF mixture. The tetrabenzylcyclene (53 g) thus obtained is dissolved in 500 ml of isopropanol and hydrogenated 8 with 10 g of Pd/C at 80 0 C and 20 bar of H 2 pressure. After the catalyst is filtered off, the reaction solution is concentrated by evaporation, and the product is recrystallized from toluene. 15.9 g (55% of theory) of cyclene is obtained as colorless crystals. Melting point 110-112 0
C.
Example 2 ml of benzylethanolamine is reacted with sulfuric acid and then with NaOH, as described in Example 1. The aqueous Nbenzylaziridine emulsion that is obtained is mixed with 2.6 1 of ethanol and heated to 50 0 C. To this end, a solution of 29.3 g of p-TsOH in 15 ml of water is added within 8 hours via a metering pump. After the addition is completed, it is refluxed for two hours. Then, the reaction mixture is mixed with a solution of g of NaOH in 20 ml of water. The precipitated product is filtered and recrystallized from 600 ml of 2:1 ethanol-THF mixture. The tetrabenzylcyclene thus obtained (55.7 g) is dissolved in 500 ml of isopropanol and hydrogenated with 10 g of Pd/C at 80 0 C and 20 bar of H 2 pressure. After the catalyst is filtered off, the reaction solution is concentrated by evaporation, and the product is recrystallized from toluene.
15.9 g (58% of theory) of cyclene is obtained as colorless crystals. Melting point 111-113 0
C.
S
9 Example 3 Like Example 1, only the tetramerization is carried out with 0.33 equivalent of methanesulfonic acid. Yield 52% cyclene.
Melting point 110-112 0
C.
Table 1: Comparative Table on Conditions and Yields of Cyclene Synthesis by Cyclotetramerization of Benzylaziridine Conditions Yield 0.03 eq. of p-TsOH, 95% EtOH, Rfl. (analogously to 12-25% Lit. 1*) 0.33 eq. of p-TsOH, 50% EtOH, 60-80 0 C (Example 1) 0.25 eq. of p-TsOH, 75% EtOH, 50-80 0 C (Example 2) 58% 0.33 eq. of MsOH, 50% EtOH, 70 0 C (Example 3) 52% Lit. 1: J. Heterocyclic Chem. 1968, 305.

Claims (4)

1. Process for the production of optionally alkyl- substituted cyclene derivatives by cyclotetramerization of optionally alkyl-substituted benzylaziri'dine derivatives, characterized in that the benzylaziridine derivative is produced from an optionally alkyl-substituted benzylethanolamine derivative in situ by reaction with sulfuric acid and subsequent reaction of the corresponding sulfuric acid ester with aqueous alkaline solution, the latter is tetramerized without isolation of the benzylaziridine derivative into a tetrabenzylcyclene derivative with the addition of 0.25-0.35 mol of a strong acid per mol of benzylaziridine derivative, and finally the benzyl groups are removed by catalytic hydrogenation.
2. Process according to claim 1, wherein the optionally alkyl-substituted cyclene derivative is 1,4,7,10- tetraazacyclododecane.
3. Process for the production of optionally alkyl- substituted tetrabenzylcyclene derivatives by cyclotetramerization of optionally alkyl-substituted benzylaziridine derivatives, wherein the benzylaziridine derivative is produced from a benzylethanolamine derivative in situ by reaction with sulfuric acid and subsequent reaction of the corresponding sulfuric acid ester with aqueous alkaline solution, and the latter is tetramerized without isolation of the benzylaziridine derivative into a tetrabenzylcyclene derivative with the addition of 0.25-0.35 mol of a strong acid per mol of~ benzylaziridine deriva tive.
4. Process according to claim 1, wherein the cyclene derivative is (2S-(2a,Sa,8a,1Il) 5,8, 11-tetramethyl-1,4,7,lo0- tetraazacyclododecane. Process according to claim 1 or 3, wherein the acid that is used is para-toluenesulfonic acid, methanesulfonic acid, or sulfuric acid. Dated this 24th day of January 2000 Schering Aktiengesellschaft *:By its Patent Attorneys of *,Davies Collison Cave
AU18772/97A 1996-02-26 1997-02-26 Process for preparing 1,4,7,10-tetraazacyclododecane and its derivatives Expired AU717720B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19608307A DE19608307C1 (en) 1996-02-26 1996-02-26 Process for the preparation of 1,4,7,10-tetraazacyclododecane and its derivatives
DE19608307 1996-02-26
PCT/EP1997/000927 WO1997031905A1 (en) 1996-02-26 1997-02-26 Process for preparing 1,4,7,10-tetraazacyclododecane and its derivatives

Publications (2)

Publication Number Publication Date
AU1877297A AU1877297A (en) 1997-09-16
AU717720B2 true AU717720B2 (en) 2000-03-30

Family

ID=7787168

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18772/97A Expired AU717720B2 (en) 1996-02-26 1997-02-26 Process for preparing 1,4,7,10-tetraazacyclododecane and its derivatives

Country Status (21)

Country Link
EP (1) EP0883610B1 (en)
JP (2) JP4745469B2 (en)
KR (1) KR100453668B1 (en)
CN (1) CN1081186C (en)
AT (1) ATE194602T1 (en)
AU (1) AU717720B2 (en)
CA (1) CA2247265C (en)
CZ (1) CZ290128B6 (en)
DE (2) DE19608307C1 (en)
DK (1) DK0883610T3 (en)
ES (1) ES2148837T3 (en)
GR (1) GR3034468T3 (en)
HK (1) HK1018618A1 (en)
IL (1) IL125419A (en)
NO (1) NO310870B1 (en)
NZ (1) NZ331520A (en)
PL (1) PL185927B1 (en)
PT (1) PT883610E (en)
SK (1) SK281972B6 (en)
WO (1) WO1997031905A1 (en)
ZA (1) ZA971672B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19608307C1 (en) * 1996-02-26 1997-08-28 Schering Ag Process for the preparation of 1,4,7,10-tetraazacyclododecane and its derivatives
CZ2005653A3 (en) * 2005-10-17 2007-01-10 Azacycles S. R. O. Process for preparing 1,4,7,10-tetraazacyclododecane and N-acyl derivatives thereof
DE102009057274B4 (en) 2009-12-02 2011-09-01 Bayer Schering Pharma Aktiengesellschaft Gadobutrol preparation using trioxobicyclo-octane
DE102010013833A1 (en) 2010-03-29 2011-09-29 Bayer Schering Pharma Aktiengesellschaft Producing gadolinium complex of N-(hydroxymethyl-dihydroxypropyl)-triscarboxymethyl-tetraazacyclododecane useful as magnetic resonance imaging contrast agent, comprises e.g. reacting cyclic compound with dimethylformamide dimethylacetal
CN101845112B (en) * 2010-06-02 2011-09-14 华东理工大学 Preparation method of high-flexibility nuclear magnetic resonance imaging contrast agents based on high molecular nanometer particles
DE102010023105A1 (en) 2010-06-04 2011-12-08 Bayer Schering Pharma Aktiengesellschaft Gadobutrol preparation in a one-pot process using DMF-acetal and N-methylimidazole
PE20141325A1 (en) 2011-04-21 2014-10-08 Bayer Ip Gmbh HIGH PURITY GADOBUTROL PREPARATION
KR102067551B1 (en) * 2018-04-12 2020-01-17 (주) 에프엔지리서치 Compounds for remediating the contaminated soil or water
CN108794417A (en) * 2018-08-04 2018-11-13 许昌恒生制药有限公司 A kind of preparation method of medical diagnosis contrast agent intermediate
EP4335461A1 (en) 2022-09-09 2024-03-13 Bayer AG Combinations of contrast agents
EP4335840A1 (en) 2022-09-09 2024-03-13 Bayer Aktiengesellschaft New contrast agents for use in diagnostic imaging

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3828023A (en) * 1971-09-13 1974-08-06 Dow Chemical Co Process for preparing cyclic oligomers of n-substituted aziridines
US6693190B1 (en) * 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
EP0813523A2 (en) * 1995-03-10 1997-12-29 Nycomed Salutar, Inc. Preparation of n-arylmethyl aziridine derivatives, 1,4,7,10-tetraazacyclododecane derivatives obtained therefrom and n-arylmethyl-ethanol-amine sulphonate esters as intermediates
DE19608307C1 (en) * 1996-02-26 1997-08-28 Schering Ag Process for the preparation of 1,4,7,10-tetraazacyclododecane and its derivatives

Also Published As

Publication number Publication date
PL185927B1 (en) 2003-09-30
AU1877297A (en) 1997-09-16
PL328468A1 (en) 1999-02-01
SK117298A3 (en) 1999-01-11
JP4745469B2 (en) 2011-08-10
ES2148837T3 (en) 2000-10-16
NZ331520A (en) 2000-01-28
CA2247265C (en) 2005-06-21
CN1081186C (en) 2002-03-20
NO983901L (en) 1998-08-25
IL125419A0 (en) 1999-03-12
NO310870B1 (en) 2001-09-10
KR100453668B1 (en) 2004-12-16
CN1211975A (en) 1999-03-24
ZA971672B (en) 1997-08-29
JP2000505467A (en) 2000-05-09
HK1018618A1 (en) 1999-12-30
CA2247265A1 (en) 1997-09-04
ATE194602T1 (en) 2000-07-15
GR3034468T3 (en) 2000-12-29
JP2009185077A (en) 2009-08-20
DK0883610T3 (en) 2000-09-25
IL125419A (en) 2001-01-11
CZ290128B6 (en) 2002-06-12
SK281972B6 (en) 2001-09-11
KR19990087248A (en) 1999-12-15
DE59702009D1 (en) 2000-08-17
CZ272198A3 (en) 2000-02-16
PT883610E (en) 2000-10-31
NO983901D0 (en) 1998-08-25
WO1997031905A1 (en) 1997-09-04
EP0883610A1 (en) 1998-12-16
DE19608307C1 (en) 1997-08-28
EP0883610B1 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
US4152326A (en) Cyclic sulphonyloxyimides
AU717720B2 (en) Process for preparing 1,4,7,10-tetraazacyclododecane and its derivatives
IE842652L (en) 2-mercapto-imidazoles
SU508199A3 (en) Method for producing morpholine derivatives
EP0252353B1 (en) 4-benzyloxy-3-pyrrolin-2-one-1-yl-acetamide, preparation and use
US5744616A (en) Process for the production of 1,4,7,10-tetraazacyclododecane and its derivatives
US4049659A (en) Process for the preparation of 4-oxo-hexahydro-pyrazinoisoquinoline derivatives
FI61880B (en) EXAMINATION OF N-ARYL SULPHONYL-N '- (3-AZABICYCLOALKYL) -URINAEMNEN
EP3717452B1 (en) Process for preparing acylated amphetamine derivatives
US4010160A (en) Process for the manufacture of 1,3-bis-(β-ethylhexyl)-5-amino-5-methyl-hexahydropyrimidine
US4289897A (en) Method for production of acylhydrazones of formyl-acetic acid ester
US4751314A (en) Preparation of tetrachloro-3-iminoisoindolin-1-one
US3951997A (en) Cyclic sulphoximides
US3026328A (en) Processes for converting l-threo-5-amino-6-phenyl dioxane to the corresponding l-erythro dioxane
KR820001122B1 (en) Process for preparing n-alkenyl moranoline derivatives
US4048169A (en) 1,3-Bis-(β-ethylhexyl)-5-nitro-5-methyl-hexahydropyrimidine-naphthalene-1,5-disulphonate
JPS6213953B2 (en)
DE3910648A1 (en) Process for preparing 2-nitrobromobenzaldehydes and 6,6'-dibromindigo
DE10231496A1 (en) Process for the preparation of high-purity, crystalline 4-amino-5,6-dimethoxypyrimidine
DE3206889A1 (en) METHOD FOR THE PRODUCTION OF 1- (4-CHLORBENZOYL) -5-METHOXY-2-METHYL-3-INDOLACETOXYACETIC ACID
CH427800A (en) Process for the preparation of new heterocyclic compounds
CS263292B1 (en) Process for preparing raw 1-amino-cis-2,6-dimethylpiperidine
DE3045680A1 (en) Cis-1,4-di:epoxy cyclohexane derivs. - used to make cis-1,3-di:amino-cyclitol antibacterial intermediates
HU206320B (en) Process for producing 8-aza-spiro/4,5/decane-7,9-dione

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)